ATAI ATAI LIFE SCIENCES BV

atai Life Sciences to Participate in Upcoming September Investor Conferences

atai Life Sciences to Participate in Upcoming September Investor Conferences

NEW YORK and BERLIN, Sept. 06, 2023 (GLOBE NEWSWIRE) --  (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in upcoming September Investor Conferences.

Details of the company’s participation are as follows:

Citi's 18th Annual BioPharma Conference

Format: 1x1 Only

Date: Thursday, September 7th

Location: Boston, MA

H.C. Wainwright 25th Annual Global Investment Conference

Format: Fireside Chat

Date and Time: Monday, September 11th at 4:00 P.M. ET

Location: New York, NY

TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit

Format: Panel

Date and Time: Wednesday, September 20th at 11:00 A.M. ET

Location: Virtual (no webcast)

The webcast for the fireside chat will be available on atai’s website under Events on the Investors section of the atai website: . A replay will be available following the live event.

About atai Life Sciences



atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders and was founded as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines to achieve clinically meaningful and sustained behavioral change in mental health patients.

atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit .

Contact Information

Investor Contact:

Media Contact:



EN
06/09/2023

Underlying

ATAIATAI LIFE SCIENCES BV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ATAI LIFE SCIENCES BV

 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

atai Life Sciences Announces Closing of Public Offering and Full Exerc...

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares Cash, cash equivalents, short-term investments and other liquid assets expected to fund operations into 2029, beyond anticipated top-line results from the first Phase 3 clinical trial of BPL-003 NEW YORK and AMSTERDAM, Oct. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced that, on October 20, 2025, the closing of its publ...

October 20, 2025 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

atai Life Sciences Announces Pricing of Public Offering of Common Shar...

atai Life Sciences Announces Pricing of Public Offering of Common Shares NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of 23,725,000 common shares, at a price of $5.48 per share. atai has granted the underwriters a 30-day option to purchase up to an additional 3,558,750 common shares at the public offering price, less the underwriting discount. All common shares to b...

October 17, 2025 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

atai Life Sciences Announces Proposed Public Offering of Common Shares

atai Life Sciences Announces Proposed Public Offering of Common Shares NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the commencement of a proposed registered underwritten offering of its common shares. atai expects to grant the underwriters a 30-day option to purchase additional common shares at the public offering price, less the underwriting discount. All common shares to be sold in the offering...

October 16, 2025 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough ...

atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression Breakthrough Therapy designation recognizes the potential of BPL-003 to deliver substantial improvement over existing therapies for patients with treatment-resistant depressionFDA designation follows previously announced Phase 2b topline data which showed rapid and durable antidepressant outcomes following a single dose of BPL-003Breakthrough Therapy designation provides intensive FDA guidance to support advancement of BPL...

October 16, 2025 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data D...

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression  Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients with treatment-resistant depression and demonstrated rapid, clinically meaningful and durable antidepressant effects, which are sustained for up to 3 monthsThe second dose of BPL-003 led to further reductions in MADRS scores from baseline, indicating that this regimen has the poten...

September 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch